Diagnosing diabetes and metabolic syndrome in men suplement na powiększenie penisa with symptoms of testosterone deficiency
It is also important for men with testosterone deficiency to be aware that this condition often co-occurs with diabetes and metabolic syndrome. Doctors may enquire about metabolic disorders such as diabetes when men present with sexual dysfunctions which may be symptoms of testosterone deficiency. This does not mean that the doctor is not taking the sexual dysfunctions seriously. On the contrary, the doctor recognises that sexual dysfunctions may not improve in men with diabetes, unless their diabetes is also treated.
Testosterone replacement therapy for men with diabetes and metabolic syndrome
Testosterone is one of the oldest marketed drugs. It has been used in TRT to resolve sexual dysfunctions and other symptoms of hypogonadism in men since the 1930s. While the key goal of TRT is to restore concentrations of testosterone in the blood, there exists considerable evidence that, in addition to resolving symptoms of testosterone deficiency, TRT improves insulin metabolism and other markers of metabolic syndrome.
For example, 83% of hypogonadal men with metabolic syndrome who received combined TRT and diet and exercise intervention reversed symptoms of the condition after one year of treatment, compared to 30% of men who received a diet and exercise intervention alone.Other studies conducted amongst men with metabolic syndrome and testosterone treatment have reported reduced body mass and body fat mass, reduced body mass index (BMI), weight and waist circumference, reduced insulin sensitivity and/or improved glucose control.
TRT has also been demonstrated effective in improving characteristics of type 2 diabetes.One study of TRT in hypogonadal men with type 2 diabetes showed significant reductions in fasting blood glucose and insulin sensitivity in the group treated with testosterone. These men also experienced reductions in waist circumference and waist-to-hip ratio and improvements in cholesterol levels.
TRT is therefore an effective treatment option for some men with metabolic disorders and testosterone deficiency. It may be an important new avenue for improving insulin resistance and the overall cardiovascular health of these men. However, your doctor will be able to advise if it is a suitable treatment option for you.
Starting testosterone replacement therapy
Some men may be reluctant to start TRT because they are afraid the treatment will negatively affect their cardiovascular health, though there is no evidence that TRT induces negative cardiovascular effects.
It it is important that men with type 2 diabetes or metabolic syndrome and testosterone deficiency do not treat their testosterone deficiency in isolation. These men should also treat their metabolic disorders, and it is particularly important that they adopt a healthy lifestyle, as both type 2 diabetes and metabolic syndrome are associated with lifestyle factors such as lack of exercise and too much fat in the diet. In some cases, medicine may also be prescribed.
Men with type 1 diabetes, a genetic condition which is not associated with lifestyle factors, can also use testosterone replacement therapy.
There are many ways by which testosterone can be administered, including orally (swallowing tablets), intramuscularly (injection into the muscle) and subdermally (absorption through the skin). Each method has its own benefits and limitations; for example, some are easier to administer than others, and some cost less.
The most appropriate form of testosterone will depend on the man being treated. Your doctor can discuss suitable options with you if this treatment is applicable.
How will sexual performance change while undergoing testosterone replacement therapy?
Most men experience low testosterone in mid or late life (past 40 or 50 years of age). At this point, some may not have been sexually active for a considerable time. Their bodies may have changed markedly in that period (particularly if their blood vessels have become damaged due to diabetes and other metabolic conditions), and their sexual response may also differ. For example, achieving erection or orgasm may be more difficult than at a younger age. As such, it is important for men who commence TRT to have realistic expectations, or they may feel that their treatment is ineffective and stop TRT.
It is also important for men to realise that even if rapid improvements to libido and other symptoms of testosterone deficiency are experienced, it is common for men to experience a plateau effect as treatment continues. This means that the improvements will level off soon after starting.
Assessing and managing lifestyle risk factors
In addition to starting TRT, it is important for hypogonadal men with metabolic conditions to manage modifiable lifestyle factors, as an unhealthy lifestyle may make their metabolic conditions worse and also reduce the effectiveness filmy pornograficzne of their treatment. Lifestyle factors play an important role in the development of type 2 diabetes mellitus, metabolic syndrome and testosterone deficiency. In particular, low levels of physical activity, unhealthy eating habits (e.g. eating too much, consuming too much fat and sugar), smoking and obesity increase the risk of each of these conditions. The risk of testosterone deficiency in men with diabetes increases further if they are also obese. Men with diabetes who maintain a healthy lifestyle may prevent the onset of testosterone deficiency.
Diet and exercise
Increasing body mass index (BMI) is associated with an increased risk of hypogonadism, and is also an important risk factor for metabolic syndrome. Thus maintaining a healthy BMI is an important component of managing testosterone deficiency. Men should:
• Consume a healthy balanced diet; and
• Be physically active.
Body Mass Index (BMI) Calculator
Enter your height and weight below to find out your BMI.
Body Mass Index:
What does this mean?
This information will be collected for educational purposes, however it will remain anonymous.
Alcohol, smoking and other recreational drug use
Alcohol, smoking and recreational drug use also increase the risk of testosterone deficiency and metabolic disorders. Men should therefore:
• Reduce alcohol consumption: Both short and long term alcohol consumption has been shown in experiments performed on animals to reduce testosterone levels. This is because it affects the function of the hypothalamus and pituitary glands, which produce hormones that regulate testosterone production;
• Quit smoking: Some studies have shown that smoking increases the risk of hypogonadism.
Work-related stress was shown in one study to be associated with an increased risk of hypogonadism, and reducing work-related stress (e.g. by finding a healthy balance between work and life) may therefore reduce the risk of testosterone deficiency.
For more information on testosterone deficiency in men, including testosterone tests and testosterone replacement therapy, see Testosterone Deficiency.
1. Allan C. Fact sheet: Diabetes and sexual and reproductive health [online]. Clayton, VIC: Andrology Australia; August 2008 [cited 23 March 2010]. Available from: URL link
2. Rice D, Brannigan RE, Campbell RK, et al. Men’s health, low testosterone and diabetes: Individualized treatment and a multidisciplinary approach [online]. Chicago, IL: American Association of Diabetes Educators; 3 October 2008 [cited 20 March 2010]. Available from: URL link
3. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673-81. [Abstract]
4. Allan CA, McLachlan RI. Testosterone deficiency in men: Diagnosis and management. Aust Fam Physician. 2003;32(6):422-7. [Abstract | Full text]
5. Kalyani RR, Dobs AS. Androgen deficiency, diabetes and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):226-34. [Abstract]
6. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007;30(2):234-8. [Abstract | Full text]
7. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. [Abstract | Full text]
8. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: Metabolic syndrome and erectile dysfunction. J Androl. 2009;30(1):10-22. [Abstract | Full text]
9. Miner MM, Sadovsky R. Evolving issues in male hypogonadism: Evaluation, management and comorbidities. Cleve Clin J Med. 2007;74(Suppl 3):S38-46. [Abstract | Full text]
10. Grossman M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834-40. [Abstract | Full text]
11. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159(5):507-14. [Abstract | Full text]
12. Morley JE, Perry HM 3rd, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53(4):424-9. [Abstract]
13. Corona G, Mannucci E, Petrone L, et al. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med. 2006;3(4):706-15.[Abstract]
14. Shabsigh R, Arver S, Channer KS, et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract. 2008;62(5):791-8. [Abstract | Full text]
15. Handelsman DJ. Testosterone: Use, misuse and abuse. Med J Aust. 2006;185(8):436-9. [Abstract | Full text]
16. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726-33. [Abstract | Full text]
17. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1):1-7. [Abstract]
18. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: A prospective cohort study. J Clin Endocrinol Metab. 2005;90(2):712-9. [Abstract | Full text]
19. Emanuele MA, Emanuele N. Alcohol and the male reproductive system. Alcohol Res Health. 2001;25(4):282-7. [Abstract | Full text]
20. Guay A, Seftel AD, Traish A. Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses. Int J Impot Res. 2010;22(1):9-19. [Abstract]
21. Svatberg J, Agledahl I, Figenschau Y, et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20(4):378-87. [Abstract]
22. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495-503. [Abstract]
23. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-37. [Abstract]
24. Kalinchenko SY. Tishova YQ, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73(5):602-12. [Abstract]
25. Handelsman DJ, Zajac JD. 11: Androgen deficiency and replacement therapy in men. Med J Aust. 2004;180(10):529-535. [Abstract | Full text]
26. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-7. [Abstract | Full text]
27. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911-7. [Abstract | Full text]